Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis by Cope, S et al.
Cope et al. Respiratory Research 2013, 14:100
http://respiratory-research.com/content/14/1/100RESEARCH Open AccessComparative efficacy of long-acting
bronchodilators for COPD - a network
meta-analysis
Shannon Cope1, James F Donohue2, Jeroen P Jansen3, Matthias Kraemer4, Gorana Capkun-Niggli4,
Michael Baldwin5, Felicity Buckley3, Alexandra Ellis3 and Paul Jones6*Abstract
Background: Clinicians are faced with an increasingly difficult choice regarding the optimal bronchodilator for
patients with chronic obstructive pulmonary disease (COPD) given the number of new treatments. The objective of
this study is to evaluate the comparative efficacy of indacaterol 75/150/300 μg once daily (OD), glycopyrronium
bromide 50 μg OD, tiotropium bromide 18 μg/5 μg OD, salmeterol 50 μg twice daily (BID), formoterol 12 μg BID,
and placebo for moderate to severe COPD.
Methods: Forty randomized controlled trials were combined in a Bayesian network meta-analysis. Outcomes of
interest were trough and post-dose forced expiratory volume in 1 second (FEV1), St. George’s Respiratory
Questionnaire (SGRQ) score and responders (≥4 points), and Transition Dyspnea Index (TDI) score and responders
(≥1 point) at 6 months.
Results: Indacaterol was associated with a higher trough FEV1 than other active treatments (difference for
indacaterol 150 μg and 300 μg versus placebo: 152 mL (95% credible interval (CrI): 126, 179); 160 mL (95% CrI:
133, 187)) and the greatest improvement in SGRQ score (difference for indacaterol 150 μg and 300 μg versus
placebo: -3.9 (95% CrI -5.2, -2.6); -3.6 (95% CrI -4.8, -2.3)). Glycopyrronium and tiotropium 18 μg resulted in the
next best estimates for both outcomes with minor differences (difference for glycopyrronium versus tiotropium
for trough FEV1 and SGRQ: 18 mL (95% CrI: -16, 51); -0.55 (95% CrI: -2.04, 0.92).
Conclusion: In terms of trough FEV1 and SGRQ score indacaterol, glycopyrronium, and tiotropium are expected to
be the most effective bronchodilators.
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Patients with chronic obstructive pulmonary disease
(COPD) experience airway obstruction, involving re-
duced lung function and health-related quality of life
due to symptoms such as breathlessness and exacerba-
tions [1]. Since COPD is a progressive disease, the main
objective of treatment is to improve lung function, pre-
vent and control symptoms, and ultimately to improve
health status. Bronchodilator medications are central to* Correspondence: pjones@sgul.ac.uk
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reproduction in any medium, provided the orsymptom management in COPD, with long-acting prep-
arations preferred over short-acting ones [1].
The classes of inhaled long-acting bronchodilators
available for COPD are long-acting β2-agonists (LABAs)
(i.e. indacaterol 75 μg, 150 μg or 300 once daily (OD),
salmeterol 50 μg twice daily (BID), or formoterol 12 μg
(BID) and long-acting muscarinic antagonists (LAMAs,
also called anticholinergic bronchodilators) (i.e. tiotro-
pium bromide 18 μg or 5 μg OD). Recently two more
LAMAs, aclidinium bromide 400 mg BID and glyco-
pyrronium bromide 44 μg OD were recently approved
by the European Medicines Agency and the Food and
Drug Administration.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ments available for COPD, clinicians are faced with an
increasingly challenging choice regarding the optimal
treatment. Since there is no head-to-head randomized
controlled trial (RCT) that evaluates all the different
monotherapies available, and it is unlikely that such
a trial will ever be performed (given the increasing
number of options available), a comprehensive system-
atic review and network meta-analysis is of interest
to synthesize the RCT evidence. The objective of the
current analysis was to evaluate the comparative effi-
cacy of long-acting bronchodilators in patients with
moderate to severe COPD in terms of lung function,
health status, and dyspnoea. Approved bronchodilators
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300 μg OD, salmeterol 50 μg BID, formoterol 12 μg
BID, tiotropium bromide 18 μg or 5 μg OD, aclidinium
bromide 200 μg OD and glycopyrronium bromide 50 μg
OD. No evidence for the approved dose of aclidinium
bromide was available at the time of the search, there-
fore results for aclidinium bromide 200 μg OD were in-
cluded in the analysis but are not presented given that
this dose has not been approved.
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Identification and selection of articles
A systematic literature search was performed to iden-
tify RCTs evaluating the efficacy of the long-acting
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Figure 3 Patient characteristics of the randomized controlled trials used for the network meta-analysis. Note: Zero values indicate
not reported unless otherwise indicated; Figure B presents the mean duration of COPD in years (red) per study and the mean age per study
(blue+ red).
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Figure 2 Network of RCTs included in the network meta-analysis. Note: The thickness of the lines corresponds to the number of RCTs
available for each treatment comparison; Two RCTs comparing aclidinium 200 μg OD to placebo were included in the network of evidence but
results were not presented since this dose has not been approved.
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A)  Trough FEV1 at 6 months
B)  Post-dose FEV1 at 6 months
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Figure 4 (See legend on next page.)
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Figure 4 Trough and post-dose FEV1 network meta-analysis results at 6 months: Difference in change from baseline (CFB) versus
placebo. Bars represent 95% Credible Interval; CFB = Change from baseline; FEV1 = Forced expiratory volume; FOR 12 = Formoterol 12 μg twice
daily (BID); GPM 50 = Glycopyrronium 50 μg once daily (OD); IND 150 = Indacaterol 150 μg OD; IND 300 = Indacaterol 300 μg OD; SAL 50 = Salmeterol
50 μg BID; TIO 5 = Tiotropium 5 μg OD; TIO 18 = Tiotropium 18 μg OD.
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http://respiratory-research.com/content/14/1/100databases were searched simultaneously for the period
of 1989 to July 2011 and the Cochrane Library was also
searched. Search terms included a combination of free-
text and thesaurus terms relevant to COPD, the treat-
ments of interest, and RCTs (see Additional file 1).
Cope et al. 2012 searched the literature from 1989–
2010 and this was updated for 2010–2011 for the treat-
ments of interest. The relevance of each citation identified
was based on title and abstract (or full-text article)
according to predefined selection criteria:
Population: Adults with COPD;
Interventions: Indacaterol 75/150/300 μg OD, tiotropium
5/18 μg OD, salmeterol 50 μg BID, formoterol 12 μg
BID, aclidinium 200/400 μg OD, and glycopyrronium
50 μg OD;
Comparators: Any of the interventions evaluated as
monotherapy or placebo;
Outcomes: Trough forced expiratory volume in 1 sec-
ond (FEV1), post-dose FEV1 (2 hours after dosing), St.
George’s Respiratory Questionnaire (SGRQ) total score
and proportion of patients with an improvement of at
least 4 units in SGRQ total score (“SGRQ Responders”
[2]), Transition Dyspnoea Index (TDI) total score and
proportion of patients with an improvement of at least 1
unit in TDI score (“TDI Responders” [3]), proportion of
patients with an exacerbation and exacerbation rate;
Study Design: RCTs.
In addition to the studies identified in the systematic
review, clinical trial reports were provided by Novartis
for trials evaluating indacaterol and glycopyrronium, all
of which had been published at the time of the search
except for the trial B2333 (NCT00792805) [4-14].
Outcomes of interest
The outcomes of interest included trough FEV1, post-dose
FEV1, SGRQ total score, SGRQ responders, TDI total
score, and TDI responders. Change from baseline was
evaluated for all continuous outcomes, with the exception
of TDI which was evaluated at follow-up. The current
analysis focuses on results at 6 months (discussed in
the following), although endpoints were also analyzed at
12 weeks (see online Additional file 1). Exacerbation out-
comes will be evaluated in separate manuscript in order to
account for differences in definitions.
Data extraction
Information related to the study and patient characteris-
tics was extracted for the included studies, which allowedfor a comprehensive assessment of the similarities and dif-
ferences across the trials. For each outcome the mean re-
sults and the associated uncertainty (i.e. standard error)
were extracted where sufficient information was available
within a two week range for each time point of interest
(i.e. between 22–26 weeks for 6 month time point). If ne-
cessary, the software DigitizIt version 1.5.8 was used to ex-
tract data from graphs presented in the publications.
Network meta-analysis
Bayesian network meta-analysis (NMA) models were
used [15-18] to simultaneously synthesize the results of
the included studies for each outcome of interest.
NMAs within the Bayesian framework involve data, a
likelihood distribution, a model with parameters, and
prior distributions [19]. The model relates the data from
the individual studies to basic parameters reflecting the
(pooled) treatment effect of each intervention relative
to placebo as the overall reference treatment. Based on
these basic parameters, the relative efficacy between
each of the interventions was obtained. For the continu-
ous outcomes a normal likelihood distribution was used
and for the binary outcomes a binomial likelihood was
used [16,17,20,21]. For each analysis, both fixed and
random effects models were evaluated. With a NMA,
randomization only holds within a trial and not across
trials. Consequently, there is the risk that patients who
were studied in different comparisons are not similar,
which may lead to consistency violations. In order to
minimize confounding bias, analyses with a constant
treatment by covariate interaction were evaluated [22] or
analyses were performed excluding specific trials to as-
sess the impact of potential treatment effect modifiers.
Potential treatment effect modifiers were identified a
priori as concomitant treatments, COPD severity, smoking
status, age, and sex. Separate analyses were performed to
evaluate the potential treatment effect modifiers given the
limited number of studies included in each analysis. Non-
informative prior distributions for the model parameters
were implemented to avoid influencing the results of the
analysis based on the prior beliefs.
For each model with and without covariates, both
fixed and random effects models were tested. The devi-
ance information criterion was used to compare the
models, which provides a measure of model fit that pe-
nalizes model complexity accordingly [23]. The random
effects model was selected unless there was sufficient
evidence to suggest the fit of the fixed effect model was
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Figure 5 (See legend on next page.)
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Figure 5 SGRQ network meta-analysis results at 6 months: Difference in change from baseline (CFB) or odds ratio (OR) for responders
versus placebo. Bars represent 95% Credible Interval; CFB = Change from baseline; FOR 12 = Formoterol 12 μg twice daily (BID); GPM
50 = Glycopyrronium 50 μg once daily (OD); IND 150 = Indacaterol 150 μg OD; IND 300 = Indacaterol 300 μg OD; OR = Odds ratio;
SAL 50 = Salmeterol 50 μg BID; SGRQ = St. George’s Respiratory Questionnaire; TIO 5 = Tiotropium 5 μg OD; TIO 18 = Tiotropium 18 μg OD.
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http://respiratory-research.com/content/14/1/100better. The analyses were performed using WinBUGS
1.4.1 statistical software [24].
The results of the NMA are presented in terms of
‘point estimates’ for the relative treatment effects and
the 95% credible intervals (95% CrI). The probability
that each treatment is best is also presented which is cal-
culated based on the proportion of Markov chain Monte
Carlo cycles in which a specific treatment ranks first out
of the total (where the ranking is based on the treatment
effect size) [25]. Figure 1 outlines the interpretation of
the results for continuous and binary outcomes, which
utilizes the probability that one treatment is better than
another (i.e. proportion of cycles in which specific treat-
ment estimate is better than the comparator).
Results
Evidence base
The systematic review identified 51 RCTs, of which 40
RCTs were included in the NMA (See Additional file 1:
Figure S1 in the online supplement) [4-14,26-52]. Eleven
RCTs that did not report the outcomes of interest within
the time frames of interest were excluded [53-63] (see
flow chart in Additional file 1: Figure S1). Figure 2 illus-
trates the network of RCTs included in the NMA and
the key study characteristics are presented in the online
supplement (see Additional file 1: Table S1).
All studies were parallel placebo-controlled multi-center
RCTs, with the exception of three RCTs that compared
active treatments only [5,13,28]. All trials were double-
blind, although three RCTs evaluated open-label tio-
tropium [7,11,51]. The RCTs were generally considered
of good quality, but the method of randomization and
concealment of treatment allocation were not always well
reported.
The study designs were mostly similar with some differ-
ences in terms of the study location and background med-
ications. The studies were predominantly European and
North American, although two trials were based in Asia
[4,12] and some trials included study centers in South
America, Africa, and Asia [6,7,14]. Most RCTs allowed pa-
tients to receive a concomitant ICS, whereas some RCTs
allowed the continued use of LABAs [26,35,37,44,45,48]
or LAMAs [30,36].
The enrolled patients had a COPD diagnosis, were
40 years of age or older and were current or ex-smokers
with a smoking history of at least 10 years. Selected RCTs
included patients with a smoking history of at least
15 years [34] or 20 years [6,7,9,12,14,41,43]. Generally,patients were required to have an FEV1/ FVC of less than
or equal to 0.70 and an FEV1 percent predicted often be-
tween 30 and 80%, although this range varied across the
studies (see Additional file 1: Table S1). Exacerbation his-
tory was reported in only five of the RCTs [8,11,31,36,42],
and two studies specified inclusion criteria with respect to
exacerbations history, requiring at least one exacerbation
over the prior one to two years [35] or one exacerbation
per year over the prior three years [30]. Figure 3 illustrates
the variation in the RCTs in terms of the proportion of
males (range: 52-99%), average age (range: 60–68 years),
duration of COPD (range: 3.8-13.1 years), proportion of
current smokers (range: 22-59%), proportion receiving
ICS during the trial (range: 0-78%), and the proportion
with severe or very severe COPD (range: 36-95%) as
reported based on the GOLD criteria or calculated as
function of the FEV1% predicted. Overall, differences were
most apparent in terms of ICS use and severity.
Network meta-analysis
The RCTs were synthesized with a network meta-
analysis. The individual study results are presented in an
online supplement (See Additional file 1: Tables S2-7).
In the base case analysis all RCTs were included without
covariates. Scenario analyses were performed to explore
the impact of differences identified in terms of concomi-
tant ICS use, concomitant LABAs or LAMAs, COPD se-
verity, and exacerbation history that were considered
most likely to cause bias. These covariates were selected
based on the extent of the variation across the RCTs and
any evidence regarding treatment effect modifiers in the
individual studies. Initially the results for the base case
analysis at 6 months are presented by outcome. Figures 4,
5, and 6 present the base case and scenario analyses at
6 months, which illustrate the results of the NMA for
each treatment versus placebo in terms of lung function,
health status, and dyspnoea, respectively. The last sec-
tion summarizes the impact of the scenario analyses
across the outcomes.
Trough and post-dose forced expiratory volume in 1 second
In terms of change from baseline (CFB) in lung function,
results from the base case analysis suggest that there is
64% probability that indacaterol 300 μg provides the
greatest improvement in trough FEV1 and an 83% prob-
ability of the greatest effect in post-dose FEV1. Indacaterol
150 μg (29%; 10%) and glycopyrronium (6%; 6%) are
less likely to provide the greatest improvement in these
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B)  TDI responders at 6 months
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#2 Scenario analysis
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baseline in each RCT
#3 Scenario analysis
Base case excluding RCTs allowing LABAs or LAMAs during 
the trial, beyond study treatments
#4 Scenario analysis
Base case adjusted for proportion patients in each RCT with 
severe or very severe COPD (based on GOLD criteria)
#5 Scenario analysis
Base case adjusted for RCTs with a high proportion of patients 
with severe or very severe COPD (≥ 60%)
#6 Scenario  analysis
Base case excluding RCTs that included only patients with a 
history of exacerbations
Figure 6 (See legend on next page.)
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Figure 6 TDI network meta-analysis results at 6 months: Difference in change from baseline (CFB) or odds ratio (OR) for responders
versus placebo. Bars represent 95% Credible Interval; CFB = Change from baseline; FOR 12 = Formoterol 12 μg twice daily (BID); GPM
50 = Glycopyrronium 50 μg once daily (OD); IND 150 = Indacaterol 150 μg OD; IND 300 = Indacaterol 300 μg OD; OR = Odds ratio; SAL
50 = Salmeterol 50 μg BID; TDI = Transition Dyspnoea Index; TIO 5 = Tiotropium 5 μg OD; TIO 18 = Tiotropium 18 μg OD.
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ability of each treatment being the best is presented in on-
line supplement (see Additional file 1: Table S8)). Tables 1
and 2 present the treatment effect estimates for each treat-
ment comparison for trough and post-dose FEV1, respect-
ively. In terms of trough FEV1 all treatments are expected
to be more efficacious than placebo. The largest difference
in trough FEV1 was between indacaterol and formoterol
(range in point estimates for difference in CFB for in-
dacaterol 150-300 μg: 93-100 mL), although indacaterol
was also more efficacious than salmeterol 50 μg (72-
79 mL), tiotropium 5 μg (41-48 mL) and tiotropium 18 μgTable 1 Results of base case NMA: Difference in intervention
6 months, 95% credible intervals, and probability that the in
Intervention
PLACEBO TIO 18 SAL 50 FOR
PLACEBO estimate 0 −115 −80 −
95% CrI −132 −100 −99 −62 −105
P(better) <1% <1% 1
TIO 18 estimate 115 0 35 5
95% CrI 100 132 12 58 8
P(better) >99% >99% 99
SAL 50 estimate 80 −35 0 2
95% CrI 62 99 −58 −12 −28
P(better) >99% 0% 81
FOR 12 estimate 60 −55 −21
95% CrI 14 105 −104 −8 −70 28
P(better) 99% 1% 19%
TIO 5 estimate 111 −3 31 5
95% CrI 85 140 −36 29 −2 65 −1
P(better) >99% 41% 97% 97
IND 150 estimate 152 37 72 9
95% CrI 126 179 8 66 42 102 42
P(better) >99% 99% >99% >9
IND 300 estimate 160 44 79 1
95% CrI 133 187 14 74 47 111 54
P(better) >99% >99% >99% >9
GPM 50 estimate 133 18 53 7
95% CrI 102 165 −16 51 17 89 18
P(better) >99% 86% >99% 99
95% CrI = 95% Credible Interval; P(better) = Probability of being the treatment being be
baseline; FEV1 = Forced expiratory volume; FOR 12= Formoterol 12 μg twice daily (BID)
OD; IND 300 = Indacaterol 300 μg OD; SAL 50= Salmeterol 50 μg BID; TIO 5 = Tiotropium(37-44 mL). Both glycopyrronium 50 μg and tiotropium
18 μg were more efficacious than formoterol 12 μg (73 mL
and 55 mL, respectively) and salmeterol 50 μg (53 mL and
35 mL, respectively) in terms of trough FEV1. The avail-
ability of data for post-dose FEV1 was more limited; al-
though the treatments were all more efficacious than
placebo no differences were detected between the active
treatments.
St. George’s Respiratory questionnaire
In terms of health status, base case results indicated
there is a ~50% probability that indacaterol 150 μg is theversus the comparator for CFB in trough FEV1 (mL) at
tervention is better than the comparator
Comparator
12 TIO 5 IND 150 IND 300 GPM 50
60 −111 −152 −160 −133
−14 −140 −85 −179 −126 −187 −133 −165 −102
% <1% <1% <1% <1%
5 3 −37 −44 −18
104 −29 36 −66 −8 −74 −14 −51 16
% 59% 1% <1% 14%
1 −31 −72 −79 −53
70 −65 2 −102 −42 −111 −47 −89 −17
% 3% <1% <1% <1%
0 −52 −93 −100 −73
−106 1 −143 −42 −145 −54 −129 −18
3% <1% <1% 1%
2 0 −41 −48 −21
106 −79 −2 −86 −9 −63 21
% 2% 1% 15%
3 41 0 −7 19
143 2 79 −39 25 −21 60
9% 98% 32% 83%
00 48 7 0 27
145 9 86 −25 39 −15 67
9% 99% 68% 90%
3 21 −19 −27 0
129 −21 63 −60 21 −67 15
% 85% 17% 10%
tter than the comparator in terms of the outcome assessed; CFB= Change from
; GPM 50 =Glycopyrronium 50 μg once daily (OD); IND 150= Indacaterol 150 μg
5 μg OD; TIO 18= Tiotropium 18 μg OD.
Table 2 Results of base case NMA: Difference in intervention versus the comparator for CFB in post-dose FEV1 (mL) at
6 months, 95% credible intervals, and probability that the intervention is better than the comparator
Intervention Comparator
PLACEBO TIO 18 SAL 50 IND 150 IND 300 GPM 50
PLACEBO estimate 0 −202 −180 −226 −276 −213
95% CrI −235 −167 −231 −128 −287 −163 −358 −192 −263 −160
P(better) <1% <1% <1% <1% <1%
TIO 18 estimate 202 0 23 −24 −0.074 −10
95% CrI 167 235 −39 82 −91 42 −158 10 −67 45
P(better) >99% 78% 22% 4% 33%
SAL 50 estimate 180 −23 0 −46 −96 −33
95% CrI 128 231 −82 39 −117 26 −190 −1 −104 40
P(better) >99% 22% 9% 2% 16%
IND 150 estimate 226 24 46 0 −50 14
95% CrI 163 287 −42 91 −26 117 −140 40 −66 92
P(better) >99% 78% 91% 13% 65%
IND 300 estimate 276 74 96 50 0 64
95% CrI 192 358 −10 158 1 190 −40 140 −33 159
P(better) >99% 96% 98% 87% 91%
GPM 50 estimate 213 10 33 −14 −64 0
95% CrI 160 263 −45 67 −40 104 −92 66 −159 33
P(better) >99% 67% 84% 35% 9%
95% CrI = 95% Credible Interval; P(better) = Probability of being the treatment being better than the comparator in terms of the outcome assessed; CFB= Change from
baseline; FEV1 = Forced expiratory volume; FOR 12= Formoterol 12 μg twice daily (BID); GPM 50 =Glycopyrronium 50 μg once daily (OD); IND 150= Indacaterol 150 μg
OD; IND 300 = Indacaterol 300 μg OD; SAL 50= Salmeterol 50 μg BID; TIO 5 = Tiotropium 5 μg OD; TIO 18= Tiotropium 18 μg OD.
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SGRQ responders, which was followed by indacaterol
300 μg (25%; 10%), formoterol 12 μg (6%; 13%), and
glycopyrronium (15%; 12%). Tables 3 and 4 present the
treatment effect estimates for each treatment compari-
son for SGRQ total score and responders, respectively.
All active treatments are expected to be more efficacious
than placebo for SGRQ total score. For SGRQ response
only indacaterol 150 μg and 300 μg, tiotropium 18 μg
and glycopyrronium 50 μg were more efficacious than
placebo, whereas the credible intervals for the other
treatment estimates versus placebo include 1. With re-
spect to SGRQ total score, indacaterol was more effica-
cious than salmeterol 50 μg (indacaterol 150 μg/300 μg
difference point estimates ranging from −2.26 to −2.56
points), as was glycopyrronium 50 μg (−1.87 points) and
tiotropium 18 μg (−1.32 points), although an improved
response was only observed for the comparison of inda-
caterol 150 μg versus salmeterol (odds ratio (OR) of 1.42).
Transition dyspnoea index
For TDI, base case results suggest there is an 86% probabil-
ity that indacaterol 300 μg is the best treatment as mea-
sured with the total score; In a responder analysis using
TDI, a 95% probability was obtained with indacaterol300 μg, which was followed by formoterol 12 μg (4%), and
indacaterol 150 μg (1%), and glycopyrronium (1%). Tables 5
and 6 present the treatment effect estimates for each treat-
ment comparison for TDI total score and responders, re-
spectively. Indacaterol 300 μg and tiotropium were more
efficacious than salmeterol 50 μg in terms of total score
(difference of 0.58 and 0.32, respectively) and indacaterol
300 μg was also more efficacious than formoterol 12 μg
(difference of 0.58). A greater response was observed with
indacaterol 300 μg in comparison to salmeterol 50 μg (OR
of 1.70), tiotropium 18 μg (OR of 1.56), glycopyrronium
50 μg (OR = 1.52) and indacaterol 150 μg (OR of 1.39).Scenario analyses
An overview of the NMA results for the continuous out-
comes at 6 months is presented in Figure 7 for the different
scenarios using symbols to summarize the main conclusion
for each comparison and analysis. Treatment effect esti-
mates were most sensitive to adjustment for disease sever-
ity (i.e. degree of airflow limitation). Results were less
sensitive to adjustment for concomitant ICS use or con-
comitant LABA or LAMA use. Minimal changes were ob-
served by excluding studies that required an exacerbation
history. Overall, the different meta-regression analyses
Table 3 Results of base case NMA: Difference in intervention versus the comparator for CFB in SGRQ total score at
6 months, 95% credible intervals, and probability that the intervention is better than the comparator
Intervention Comparator
PLACEBO TIO 18 SAL 50 FOR 12 TIO 5 IND 150 IND 300 GPM 50
PLACEBO estimate 0.00 2.63 1.31 2.58 2.21 3.87 3.57 3.18
95% CrI 1.91 3.31 0.48 2.21 0.60 4.53 0.78 3.61 2.56 5.17 2.30 4.84 1.78 4.56
P(better) <1% <1% 1% <1% <1% <1% <1%
TIO 18 estimate −2.63 0.00 −1.32 −0.05 −0.42 1.24 0.94 0.55
95% CrI −3.31 −1.91 −2.32 −0.21 −2.09 2.01 −1.98 1.17 −0.15 2.63 −0.41 2.31 −0.92 2.04
P(better) >99% 99% 52% 72% 4% 8% 22%
SAL 50 estimate −1.31 1.32 0.00 1.27 0.91 2.56 2.26 1.87
95% CrI −2.21 −0.48 0.21 2.32 −0.92 3.36 −0.82 2.50 1.03 4.00 0.74 3.75 0.21 3.44
P(better) >99% 1% 12% 13% <1% <1% 1%
FOR 12 estimate −2.58 0.05 −1.27 0.00 −0.37 1.30 1.00 0.61
95% CrI −4.53 −0.60 −2.01 2.09 −3.36 0.92 −2.78 2.05 −0.97 3.56 −0.96 2.98 −1.81 3.02
P(better) 99% 48% 88% 62% 13% 16% 31%
TIO 5 estimate −2.21 0.42 −0.91 0.37 0.00 1.67 1.36 0.97
95% CrI −3.61 −0.78 −1.17 1.98 −2.50 0.82 −2.05 2.78 −0.29 3.58 −0.53 3.26 −1.01 2.94
P(better) >99% 28% 87% 38% 4% 7% 15%
IND 150 estimate −3.87 −1.24 −2.56 −1.30 −1.67 0.00 −0.30 −0.70
95% CrI −5.17 −2.56 −2.63 0.15 −4.00 −1.03 −3.56 0.97 −3.58 0.29 −1.82 1.24 −2.59 1.28
P(better) >99% 96% >99% 87% 96% 65% 77%
IND 300 estimate −3.57 −0.94 −2.26 −1.00 −1.36 0.30 0.00 −0.39
95% CrI −4.84 −2.30 −2.31 0.41 −3.75 −0.74 −2.98 0.96 −3.26 0.53 −1.24 1.82 −2.28 1.47
P(better) >99% 92% >99% 84% 93% 35% 66%
GPM 50 estimate −3.18 −0.55 −1.87 −0.61 −0.97 0.70 0.39 0.00
95% CrI −4.56 −1.78 −2.04 0.92 −3.44 −0.21 −3.02 1.81 −2.94 1.01 −1.28 2.59 −1.47 2.28
P(better) >99% 78% 99% 69% 85% 23% 34%
95% CrI = 95% Credible Interval; P(better) = Probability of being the treatment being better than the comparator in terms of the outcome assessed; CFB= Change from
baseline; FOR 12= Formoterol 12 μg twice daily (BID); GPM 50 =Glycopyrronium 50 μg once daily (OD); IND 150= Indacaterol 150 μg OD; IND 300 = Indacaterol 300 μg
OD; SAL 50= Salmeterol 50 μg BID; SGRQ= St. George’s Respiratory Questionnaire; TIO 5 = Tiotropium 5 μg OD; TIO 18 = Tiotropium 18 μg OD.
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mates and did not alter the interpretation.
Discussion
The objective of this analysis was to compare the efficacy
of individual bronchodilators for patients with moderate to
severe COPD in terms of lung function, health status, and
dyspnoea. Based on the results of the NMA at 6 months,
indacaterol resulted in the best treatment at either the 150
or 300 μg dose, depending on the outcome assessed, al-
though indacaterol was not always more efficacious than
the alternative bronchodilators and differences versus other
active treatments were small.
Thresholds for clinically important differences have
been established for active treatments versus placebo in
terms of FEV1, SGRQ total score, and TDI total score.
Although comparisons of alternative active treatments
may not be expected to reach these thresholds, in theabsence of any clear guidance for interpretation of active
treatments these thresholds have been used to help iden-
tify whether differences between treatments are clinically
relevant. FEV1 thresholds defined to evaluate whether an
active treatment has demonstrated a clinically meaning
difference versus placebo (i.e. 100 mL-140 mL [64-66])
suggest that none of the differences in lung function be-
tween the active treatments were clinically meaningful
in the analysis of all studies without covariates (base-
case analysis). In terms of health status, improvements
in SGRQ total score were identified for indacaterol 150
and 300 μg, glycopyrronium 50 μg, and tiotropium 18
μg in comparison to salmeterol, although differences
were less than the 4 units for a clinically relevant differ-
ence. Only indacaterol 150 μg led to a clinically relevant
response relative to salmeterol with respect to SGRQ.
The estimated differences between treatments in terms
of TDI total score were smaller than the threshold for
Table 4 Results of base case NMA: Difference in intervention versus the comparator for SGRQ responders at 6 months
in terms of odds ratios (ORs), 95% credible intervals, and probability that the intervention is better than the
comparator
Comparator
Intervention PLACEBO TIO 18 SAL 50 FOR 12 TIO 5 IND 150 IND 300 GPM 50
PLACEBO estimate 1.00 0.71 0.84 0.71 0.70 0.60 0.67 0.69
95% CrI 0.61 0.83 0.70 1.00 0.48 1.07 0.49 1.00 0.47 0.77 0.52 0.87 0.52 0.92
P(better) <1% 9% 5% 3% <1% <1% 1%
TIO 18 estimate 1.41 1.00 1.20 1.01 0.99 0.84 0.95 0.97
95% CrI 1.21 1.64 0.92 1.58 0.65 1.58 0.66 1.50 0.64 1.14 0.71 1.29 0.71 1.35
P(better) >99% 92% 52% 48% 11% 35% 43%
SAL 50 estimate 1.19 0.84 1.00 0.84 0.83 0.71 0.79 0.81
95% CrI 1.00 1.42 0.63 1.09 0.53 1.34 0.54 1.27 0.52 0.96 0.57 1.11 0.56 1.17
P(better) 91% 8% 22% 15% 2% 8% 12%
FOR 12 estimate 1.40 0.99 1.18 1.00 0.98 0.84 0.94 0.96
95% CrI 0.93 2.10 0.63 1.55 0.74 1.90 0.58 1.68 0.53 1.33 0.63 1.42 0.59 1.58
P(better) 95% 48% 78% 47% 20% 36% 44%
TIO 5 estimate 1.42 1.01 1.20 1.02 1.00 0.85 0.95 0.98
95% CrI 1.00 2.03 0.67 1.52 0.79 1.87 0.60 1.74 0.56 1.32 0.63 1.49 0.62 1.55
P(better) 97% 52% 85% 53% 19% 39% 46%
IND 150 estimate 1.67 1.19 1.42 1.20 1.18 1.00 1.12 1.15
95% CrI 1.29 2.13 0.88 1.57 1.04 1.92 0.75 1.88 0.76 1.79 0.83 1.51 0.78 1.67
P(better) >99% 89% 98% 80% 81% 79% 79%
IND 300 estimate 1.49 1.06 1.26 1.07 1.05 0.89 1.00 1.03
95% CrI 1.15 1.91 0.78 1.41 0.90 1.76 0.71 1.59 0.67 1.60 0.66 1.20 0.70 1.49
P(better) >99% 65% 92% 64% 61% 21% 56%
GPM 50 estimate 1.45 1.03 1.23 1.04 1.02 0.87 0.97 1.00
95% CrI 1.08 1.94 0.74 1.42 0.85 1.79 0.63 1.71 0.65 1.61 0.60 1.27 0.67 1.43
P(better) 99% 57% 88% 56% 54% 21% 44%
95% CrI = 95% Credible Interval; P(better) = Probability of being the treatment being better than the comparator in terms of the outcome assessed; FOR
12 = Formoterol 12 μg twice daily (BID); GPM 50 = Glycopyrronium 50 μg once daily (OD); IND 150 = Indacaterol 150 μg OD; IND 300 = Indacaterol 300 μg OD;
OR = Odds ratio; SAL 50 = Salmeterol 50 μg BID; SGRQ = St. George’s Respiratory Questionnaire; TIO 5 = Tiotropium 5 μg OD; TIO 18 = Tiotropium 18 μg OD.
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portion of patients had a clinically relevant TDI response
with indacaterol 300 μg in comparison to salmeterol
50 μg and tiotropium 18 μg.
The validity of the findings depends on the quality of
the RCTs and the extent of any violations in the similar-
ity and consistency assumptions across studies [22]. In a
network meta-analysis of RCTs involving multiple treat-
ment comparisons, the randomization holds only within
the individual trials, and not across trials. If the different
direct comparisons show systematic differences in study
and patient characteristics, and these differences are
treatment effect modifiers, then the estimates of any in-
direct comparison as obtained with the network meta-
analysis will be biased. With a meta-regression analysis
we aim to minimize this confounding bias by adjusting
for inconsistencies in the evidence base.The trials included in the network meta-analysis were
generally of good quality. All trials were blinded with the
exception of open label tiotropium 18 μg in three RCTs,
which has been shown to be comparable to blinded re-
sults for FEV1, although with some minimal bias in-
troduced on more subjective measures [67]. However,
some differences across trials were identified in terms of
concomitant ICS use, concomitant LABA or LAMA use,
the severity of COPD and the exacerbation history re-
quirements. Individual scenario analyses were performed
to evaluate these differences using a either a meta-
regression model or by excluding specific studies that
differed in terms of the characteristics identified. Overall,
the interpretation of findings obtained with analysis
based on all studies without adjustment for covariates
(base-case analysis) was the same as obtained with the
scenario analyses in the majority of cases. Only a few
Table 5 Results of base case NMA: Difference in intervention versus the comparator for TDI total score at 6 months,
95% credible intervals, and probability that the intervention is better than the comparator
Intervention Comparator
PLACEBO TIO 18 SAL 50 FOR 12 IND 150 IND 300 GPM 50
PLACEBO estimate 0.00 −0.96 −0.64 −0.65 −0.93 −1.23 −0.92
95% CrI −1.20 −0.74 −0.91 −0.38 −1.09 −0.20 −1.20 −0.65 −1.51 −0.95 −1.27 −0.58
P(better) <1% <1% <1% <1% <1% <1%
TIO 18 estimate 0.96 0.000 0.32 0.32 0.04 −0.27 0.046
95% CrI 0.741 1.195 0.012 0.64 −0.17 0.81 −0.28 0.37 −0.59 0.07 −0.33 0.43
P(better) >99% 98% 90% 59% 6% 60%
SAL 50 estimate 0.64 −0.32 0.00 0.00 −0.29 −0.58 −0.28
95% CrI 0.38 0.91 −0.64 −0.01 −0.52 0.51 −0.63 0.06 −0.96 −0.22 −0.71 0.14
P(better) >99% 2% 49% 5% <1% 10%
FOR 12 estimate 0.65 −0.32 0.00 0.00 −0.28 −0.58 −0.27
95% CrI 0.20 1.09 −0.81 0.17 −0.51 0.52 −0.77 0.22 −1.02 −0.14 −0.83 0.29
P(better) >99% 10% 51% 13% 1% 17%
IND 150 estimate 0.93 −0.04 0.29 0.28 0.00 −0.30 0.01
95% CrI 0.65 1.20 −0.37 0.28 −0.06 0.63 −0.22 0.77 −0.63 0.02 −0.43 0.45
P(better) >99% 41% 95% 87% 3% 51%
IND 300 estimate 1.23 0.27 0.58 0.58 0.30 0.00 0.31
95% CrI 0.95 1.51 −0.07 0.59 0.22 0.96 0.14 1.02 −0.02 0.63 −0.13 0.75
P(better) >99% 94% >99% 99% 97% 92%
GPM 50 estimate 0.92 −0.05 0.28 0.27 −0.01 −0.31 0.00
95% CrI 0.58 1.27 −0.43 0.33 −0.14 0.71 −0.29 0.83 −0.45 0.43 −0.75 0.13
P(better) >99% 40% 90% 83% 49% 8%
95% CrI = 95% Credible Interval; P(better) = Probability of being the treatment being better than the comparator in terms of the outcome assessed; FOR 12= Formoterol
12 μg twice daily (BID); GPM 50=Glycopyrronium 50 μg once daily (OD); IND 150 = Indacaterol 150 μg OD; IND 300= Indacaterol 300 μg OD; SAL 50 = Salmeterol 50 μg
BID; TIO 5 = Tiotropium 5 μg OD; TIO 18 = Tiotropium 18 μg OD; TDI = Transitional Dyspnoea Index.
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the comparative effects.
Although we went to great lengths to assess whether
the network meta-analysis was biased by systematic dif-
ferences between studies, the meta-regression analysis
was based on study level data which has limitations. First
of all, it was not feasible to include all covariates of
interest simultaneously due to the limited number of
data points. Second, study and patient characteristics
were not consistently reported. For example, limited in-
formation was available for the exacerbation history of
patients and therefore it was only possible to exclude tri-
als that clearly required an exacerbation history. Simi-
larly, information regarding COPD comorbidities was
not consistently reported across the RCTs, so these po-
tential differences could not be explored. Third, it is well
known that meta-regression analysis based on study
level data can be prone to ecological bias, which means
that association between study level patient characteris-
tics and the treatment effects may not reflect the
individual-level effect modification of that covariate. Assuch, it has to be accepted that there is the risk of re-
sidual confounding bias.
This study aimed to provide a comprehensive evidence
base. However, it was not possible to capture all recent
studies. The literature search did not capture the AC-
CORD [68] or ATTAIN [69] trials evaluating aclidinium
400 μg BID that were published after the date of the
search, and an updated analysis including these studies
is of interest. Moreover, data for new bronchodilators
that may be of interest, such as vilanterol, olodaterol,
and unmeclidinium, were not available and may necessi-
tate an updated analysis including these treatments in
future. It should also be noted, that in order to include
the indacaterol and glycopyrronium trials that were
not yet published at the time of the literature search,
Novartis provided the corresponding clinical study re-
ports. No attempt was made to obtain study reports
from manufacturers of formoterol, salmeterol, or tio-
tropium. This may have induced a bias, but it is unlikely
that key positive results were withheld from the primary
papers.
Table 6 Results of base case NMA: Difference in intervention versus the comparator for TDI responders at 6 months in
terms of odds ratios (ORs), 95% credible intervals, and probability that the intervention is better than the comparator
Comparator
Intervention PLACEBO TIO 18 SAL 50 FOR 12 IND 150 IND 300 GPM 50
PLACEBO estimate 1.00 0.61 0.67 0.53 0.55 0.39 0.60
95% CrI 0.51 0.73 0.54 0.82 0.38 0.74 0.44 0.68 0.31 0.49 0.47 0.76
P(better) <1% <1% <1% <1% <1% <1%
TIO 18 estimate 1.63 1.00 1.09 0.86 0.89 0.64 0.97
95% CrI 1.37 1.96 0.88 1.37 0.59 1.26 0.70 1.14 0.50 0.83 0.75 1.27
P(better) >99% 78% 22% 17% <1% 42%
SAL 50 estimate 1.50 0.92 1.00 0.79 0.82 0.59 0.89
95% CrI 1.21 1.84 0.73 1.14 0.54 1.17 0.63 1.06 0.44 0.78 0.66 1.21
P(better) >99% 22% 11% 6% <1% 23%
FOR 12 estimate 1.90 1.16 1.26 1.00 1.03 0.74 1.13
95% CrI 1.35 2.66 0.80 1.68 0.85 1.87 0.70 1.52 0.53 1.04 0.74 1.71
P(better) >99% 78% 89% 56% 4% 72%
IND 150 estimate 1.83 1.12 1.22 0.97 1.00 0.72 1.09
95% CrI 1.48 2.28 0.88 1.44 0.95 1.58 0.66 1.43 0.55 0.94 0.80 1.50
P(better) >99% 83% 94% 44% 1% 72%
IND 300 estimate 2.55 1.56 1.70 1.35 1.39 1.00 1.52
95% CrI 2.04 3.19 1.21 2.02 1.28 2.28 0.97 1.89 1.07 1.81 1.10 2.10
P(better) >99% >99% >99% 96% 99% 99%
GPM 50 estimate 1.68 1.03 1.12 0.89 0.92 0.66 1.00
95% CrI 1.32 2.14 0.79 1.34 0.82 1.52 0.58 1.35 0.67 1.26 0.48 0.91
P(better) >99% 58% 77% 28% 28% 1%
95% CrI = 95% Credible Interval; P(better) = Probability of being the treatment being better than the comparator in terms of the outcome assessed; FOR
12 = Formoterol 12 μg twice daily (BID); GPM 50 = Glycopyrronium 50 μg once daily (OD); IND 150 = Indacaterol 150 μg OD; IND 300 = Indacaterol 300 μg OD;
OR = Odds ratio; SAL 50 = Salmeterol 50 μg BID; TIO 5 = Tiotropium 5 μg OD; TIO 18 = Tiotropium 18 μg OD; TDI = Transitional Dyspnoea Index.
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but results at 12 weeks are available as well (online
Additional file 1). Results at 6 months provide better
insight regarding efficacy over a longer term than the
12 week results, particularly for patient reported out-
comes, but data for the approved dose of indacaterol in
the United States (75 μg) are only available at 12 weeks.
There is also a need to evaluate whether there is sufficient
data available to inform decision-makers regarding longer
term comparative efficacy. One potential limitation of the
current analysis is that some studies were excluded from
the analysis if the outcomes reported deviated by more
than 2 weeks from the specified time points of interest.
For example, the analyses of SGRQ and trough FEV1 at
the 6 months excluded data from Stockley et al. 2006
(n = 634), and Chan et al. 2007 (n = 913), which may have
influenced the results somewhat for salmeterol and
tiotropium. However, given the large number of studies in-
cluded for these treatments, the exclusion of these trials is
not expected to have a large impact. Similarly, only post-
dose FEV1 results at 2 hours after dosing were included,
which reflected the most commonly reported time point.Although several network meta-analyses have been pub-
lished in the area of COPD, it is challenging to compare the
current results to previous analyses. Earlier analyses did
not include indacaterol [70,71], and more recent analyses
have focussed on comparisons to fixed-dose combinations
[72,73] or were not as comprehensive in terms of the data
or outcomes evaluated. For example, the analysis by Cope
et al. 2012 [74] was restricted to four trials from the
indacaterol trial program and the review by Cope et al.
2012 [75] focussed on trough FEV1 and SGRQ total score
at 12 weeks. Furthermore, these studies did not include evi-
dence regarding treatments such as glycopyrronium 50 μg
or tiotropium 5 μg. Recent meta-analyses restricted the evi-
dence to RCTs that directly compared the active interven-
tions of interest [76,77] or placebo controlled trials [78]
without considering the full network of evidence. Also, in
some cases alternative LABAs were pooled together (i.e.
formoterol, salmeterol, and/or indacaterol), despite poten-
tial differences in these treatments, preventing a clear com-
parison to the current results. Therefore, to our knowledge,
the current study generates new evidence regarding the effi-
cacy of monotherapies for moderate to severe COPD.
Tr
ou
gh
 F
EV
1
Po
st
-
do
se
 
FE
V 1
SG
RQ
 
sc
or
e
TD
I s
co
re
Tr
ou
gh
 F
EV
1
Po
st
-
do
se
 
FE
V 1
SG
RQ
 
sc
or
e
TD
I s
co
re
Tr
ou
gh
 F
EV
1
Po
st
-
do
se
 
FE
V 1
SG
RQ
 
sc
or
e
TD
I s
co
re
Tr
ou
gh
 F
EV
1
Po
st
-
do
se
 
FE
V 1
SG
RQ
 
sc
or
e
TD
I s
co
re
Tr
ou
gh
 F
EV
1
Po
st
-
do
se
 
FE
V 1
SG
RQ
 
sc
or
e
TD
I s
co
re
Tr
ou
gh
 F
EV
1
Po
st
-
do
se
 
FE
V 1
SG
RQ
 
sc
or
e
TD
I s
co
re
Tr
ou
gh
 F
EV
1
Po
st
-
do
se
 F
EV
1
SG
RQ
 
sc
or
e
TD
I s
co
re
Tr
ou
gh
 F
EV
1
Po
st
-
do
se
 
FE
V 1
SG
RQ
 
sc
or
e
TD
I s
co
re
#
1
2
3
4
5
6
1
2
3
4
5
6
1
2
3
4
5
6
1
2
3
4
5
6
1
2
3
4
5
6
1
2
3
4
5
6
1
2
3
4
5
6
1
2
3
4
5
6
 GPM 50
Placebo TIO 18 SAL 50
 Placebo
 TIO 18
 SAL 50
 FOR 12
 TIO 5
IND 150 IND 300 GPM 50
 IND 150
 IND 300
FOR 12 TIO 5
Figure 7 Overview of the network meta-analysis results for trough FEV1, post-dose FEV1, SGRQ total score, and TDI total score at 6
months. Symbols are explained in Figure 1; FEV1 = Forced expiratory volume in 1 second; FOR 12 = Formoterol 12 μg twice daily (BID);
GPM 50 = Glycopyrronium 50 μg once daily (OD); IND 150 = Indacaterol 150 μg OD; IND 300 = Indacaterol 300 μg OD; SAL 50 = Salmeterol 50 μg
BID; SGRQ= St. George’s Respiratory Questionnaire; TDI = Transition Dyspnoea Index; TIO 5 = Tiotropium 5 μg OD; TIO 18 = Tiotropium 18 μg OD.
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http://respiratory-research.com/content/14/1/100The efficacy outcomes analyzed here provide insight into
a broad range of clinically relevant outcomes. FEV1 is often
a primary endpoint and reflects an important outcome
from a clinical and regulatory perspective, providing a re-
producible and objective measurement of airflow limitation
[1]. SGRQ and TDI are based on validated instruments
and provide unique insight into the patient perspective. Ex-
acerbations reflect another key outcome given their impact
on quality of life and resource utilization, although a separ-
ate publication will be developed in order to capture the
complexity associated with these outcomes. It should be
acknowledged that no safety outcomes were assessed,
which is a critical aspect of decision-making that has been
addressed by others [79-83].
In conclusion, based on the results of the NMA, inda-
caterol, glycopyrronium, and tiotropium are expected to
be the most favourable bronchodilators in terms of lung
function, health status, and dyspnoea at six months, al-
though differences were only clinically meaningful for
indacaterol 150 μg in comparison to salmeterol in terms
of SGRQ and for indacaterol 300 μg in comparison to
salmeterol, tiotropium and formoterol in terms of TDI
response.Additional file
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